Search results for "Interferon"

showing 10 items of 963 documents

Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C

2007

OBJECTIVES: The aims of this study were to investigate the expression of cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) in chronic hepatitis C (CHC) by immunohistochemistry, based on the hypothesis that COXs expression could vary according to genotype, viral load, liver steatosis, BMI and response to therapy and to determine whether the addition of selective COX inhibitors could have a rationale in increasing the efficacy of antiviral therapy. METHODS: We used 35 formalin-fixed, paraffin-embedded liver tissue samples obtained by needle biopsy from patients with CHC (17F/18M) with one of two types of genotype (1b and 3a). The presence of COX-1 and COX-2 in the cytoplasm of hepatocyt…

MaleSteatosisGene ExpressionHepacivirusChronic hepatitis CGastroenterologychemistry.chemical_compoundmedicine.diagnostic_testFatty liverGastroenterologyMiddle AgedImmunohistochemistryRecombinant ProteinsCyclooxygenaseTreatment OutcomeLiverRNA ViralFemaleViral loadmedicine.drugAdultmedicine.medical_specialtyAdolescentGenotypeCombination therapyAlpha interferonInterferon alpha-2Antiviral AgentsInternal medicineRibavirinBiopsymedicineHumansInterferon alfaAgedStaining and LabelingHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C AntibodiesHepatitis C Chronicmedicine.diseasechemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesImmunologyCyclooxygenase 1SteatosisbusinessInterferon-αEuropean Journal of Gastroenterology & Hepatology
researchProduct

gd T cells condition dendritic cells in vivo for priming pulmonary CD8 T cell responses against Mycobacterium tuberculosis

2006

gammadelta T cells and dendritic cells are quickly recruited to the lungs shortly after intranasal vaccination with BCG, but the functional in vivo interplay between these two cell populations and its role in the induction of adaptive immune responses is unclear. Using TCR-deficient mice and bone marrow chimeras, we show here that gammadelta T cells provide a non-redundant early source of IFN-gamma in vivo, which enhances IL-12 production by lung dendritic cells. The in vivo-conditioned dendritic cells, in turn, prime a more efficient lung CD8 T cell response against Mycobacterium tuberculosis. Thus, strategies exploiting gammadelta T cell function and IFN-gamma production could be valuable…

MaleT cellImmunologyBiologyCD8-Positive T-LymphocytesLymphocyte ActivationInterleukin 21Interferon-gammaMiceT-Lymphocyte SubsetsmedicineImmunology and AllergyCytotoxic T cellAnimalsTuberculosisIL-2 receptorAntigen-presenting cellLungFollicular dendritic cellsReceptors Antigen T-Cell gamma-deltaDendritic CellsMycobacterium tuberculosisNatural killer T cellFlow CytometryInterleukin-12Mice Mutant StrainsMice Inbred C57BLmedicine.anatomical_structureImmunologyInterleukin 12Female
researchProduct

Cost effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

2013

Background & Aims Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC. Methods The available published literature provided the data source. The target population was made up of previously treated Caucasian patients with G1 CHC and these were evaluated over a lifetime horizo…

MaleTVRCost effectivenessCost-Benefit AnalysisPIPeginterferon-alfaBOCHepacivirusBOC Boceprevir CHC Cost-effectiveness DT G1 ICER NR PAR PI PegIFN RBV RR TVR Telaprevir boceprevir chronic hepatitis C dual therapy genotype 1 incremental cost-effectiveness ratio non-response partial response pegylated interferon protease inhibitors relapse ribavirin telaprevirTelaprevirTelaprevirchemistry.chemical_compoundPegylated interferonnon-responseboceprevirincremental cost-effectiveness ratioRBVTreatment FailureDThealth care economics and organizationsRandomized Controlled Trials as Topicrelapsecost effectivenessICERMiddle AgedMarkov ChainsModels EconomicItalyQuality-Adjusted Life YearsSettore SECS-P/02 - politica economicaSettore SECS-S/01 - StatisticaIncremental cost-effectiveness ratioOligopeptidesmedicine.drugmedicine.medical_specialtyGenotypeProlineribavirinSettore MED/12 - GASTROENTEROLOGIAprotease inhibitorsNRRRAntiviral AgentsInternal medicineBoceprevirG1medicineHumanschronic hepatitis Cpegylated interferongenotype 1Hepatologybusiness.industryRibavirindual therapyHepatitis C ChronicQuality-adjusted life yearSurgeryCHCPegIFNchemistryCost-effectivenesspartial responsebusinessPAR
researchProduct

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with H…

2016


 
 
 
 
 
 Background & Aims: Smoking has multiple effects on factors influencing hepatitis C and antiviral therapy, including lipid metabolism, fibrosis, platelet count and adherence aspects. The aim of this analysis was to determine the impact of smoking on hepatitis C virus antiviral therapy.
 Methods: Data of two cohorts of an observational multicenter study including therapy-naïve patients infected with genotype 1 hepatitis C virus (HCV) treated with dual antiviral therapy (n=7,796) with pegylated interferon alpha 2a in combination with ribavirin, or triple antiviral therapy (n=1,122) containing telaprevir or boceprevir, were analysed.
 Resu…

MaleTime Factors030508 substance abuseHepacivirusmedicine.disease_causeGastroenterologyTelaprevirPolyethylene Glycolschemistry.chemical_compound0302 clinical medicineRisk FactorsGermanyOdds RatioAged 80 and overSmokingGastroenterologyHepatitis CMiddle AgedViral LoadHepatitis CRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemale0305 other medical scienceViral loadOligopeptidesmedicine.drugAdultmedicine.medical_specialtyAdolescentGenotypeProlineHepatitis C virusAlpha interferonAntiviral Agents03 medical and health sciencesYoung AdultBoceprevirInternal medicineRibavirinmedicineHumansProtease inhibitor (pharmacology)Protease InhibitorsAgedbusiness.industryRibavirinInterferon-alphamedicine.diseaseVirology030227 psychiatryLogistic ModelschemistryMultivariate AnalysisbusinessJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian…

2014

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing-remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment. © Th…

MaleTime FactorsThyroid GlandAutoimmunityAdverse effectmedicine.disease_causemultiple sclerosisGastroenterologythyroidAutoimmunityImmunosuppressive AgentRisk FactorsRetrospective StudiePrevalenceinterferon betaThyroidadverse effects; autoimmunity; glatiramer acetate; interferon beta; thyroid; multiple sclerosisMiddle AgedTreatment Outcomemedicine.anatomical_structureItalyNeurologymultiple sclerosiThyroid autoimmunityCohortFemaleSettore MED/26 - NeurologiaThyroid functionImmunosuppressive AgentsInterferon beta-1aHumanInterferon beta-1bmedicine.drugAdultmedicine.medical_specialtyTime FactorThyroid DiseaseRisk AssessmentYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansGlatiramer acetateAdverse effectRetrospective Studiesbusiness.industryRisk FactorMultiple sclerosisGlatiramer Acetatemedicine.diseaseThyroid DiseasesImmunologyadverse effectsNeurology (clinical)business
researchProduct

Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients

2021

Abstract Background Autoimmune Polyglandular Syndrome type 1 (APS-1) is a rare recessive inherited disease, caused by AutoImmune Regulator (AIRE) gene mutations and characterized by three major manifestations: chronic mucocutaneous candidiasis (CMC), chronic hypoparathyroidism (CH) and Addison’s disease (AD). Methods Autoimmune conditions and associated autoantibodies (Abs) were analyzed in 158 Italian patients (103 females and 55 males; F/M 1.9/1) at the onset and during a follow-up of 23.7 ± 15.1 years. AIRE mutations were determined. Results The prevalence of APS-1 was 2.6 cases/million (range 0.5–17 in different regions). At the onset 93% of patients presented with one or more component…

MaleTranscription FactorEndocrinology Diabetes and MetabolismAutoimmune hepatitisGene mutationGastroenterologyChronic mucocutaneous candidiasisEndocrinologyAddison DiseaseAutoimmune Polyglandular Syndrome type 1 (APS-1)PrevalenceMedicineChronic mucocutaneous candidiasisPolyendocrinopathies AutoimmuneCandidiasis Chronic MucocutaneouAddison’s disease AIRE gene mutations Autoimmune Polyglandular Syndrome type 1 (APS-1) Autoimmune-poly-endocrine-candidiasis-ectodermal-dystrophy (APECED) Chronic hypoparathyroidism Chronic mucocutaneous candidiasis Interferon autoantibodiesCandidiasis Chronic MucocutaneousAIRE gene mutations; Addison’s disease; autoimmune polyglandular syndrome type 1 (APS-1); autoimmune-poly-endocrine-candidiasis-ectodermal-dystrophy (APECED); chronic hypoparathyroidism; chronic mucocutaneous candidiasis; interferon autoantibodiesAutoimmune regulatorAutoantibodieItalyInterferon autoantibodieAddison's diseaseInterferon Type IOriginal ArticleFemaleChronic hypoparathyroidismHumanAdultmedicine.medical_specialtyAutoimmune GastritisHypoparathyroidismAddison’s diseaseAIRE gene mutationsInternal medicineInterferon autoantibodiesHumansMortalityAutoantibodiesAddison’s disease; AIRE gene mutations; Autoimmune Polyglandular Syndrome type 1 (APS-1); Autoimmune-poly-endocrine-candidiasis-ectodermal-dystrophy (APECED); Chronic hypoparathyroidism; Chronic mucocutaneous candidiasis; Interferon autoantibodiesbusiness.industryChronic mucocutaneous candidiasiAIRE gene mutationAutoantibodymedicine.diseaseAutoimmune-poly-endocrine-candidiasis-ectodermal-dystrophy (APECED)Interferon autoantibodies.Autoimmune polyendocrine syndrome type 1MutationbusinessTranscription Factors
researchProduct

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

2013

International audience; Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV alone in previously untreated adults with chronic hepatitis C genotype 1. We evaluate the relationship of incident anemia with triple therapy. A total of 1,097 patients received a 4-week lead-in of PegIFN/RBV followed by: (1) placebo plus PegIFN/RBV for 44 weeks (PR48); (2) BOC plus PegIFN/RBV using response-guided therapy (BOC/RGT); and (3) BOC plus PegIFN/RBV for 44 weeks (BOC/PR48). The management of anemia (hemoglobin [Hb]<10 g/dL) included RBV dose reduction and/or erythropoietin (EPO) use. A total of 1,080…

Male[SDV]Life Sciences [q-bio]MedizinGastroenterologyPolyethylene GlycolsPlaceboschemistry.chemical_compoundHemoglobins0302 clinical medicinehemic and lymphatic diseasesMedicine030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaInterferon-alpha; Serine Proteinase Inhibitors; Proline; Recombinant Proteins; Hematinics; Humans; Ribavirin; Anemia; Antiviral Agents; Drug Therapy Combination; Erythropoietin; Hemoglobins; Adult; Treatment Outcome; Placebos; Polyethylene Glycols; Hepatitis C Chronic; Female; MaleAnemiaHepatitis CHepatitis CRecombinant Proteins3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeCombinationPeginterferon alfa-2b030211 gastroenterology & hepatologyDrug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsProlineAnemiaInterferon alpha-2PlaceboAntiviral Agentsprotease inhibitor03 medical and health sciencesDrug TherapyInternal medicineBoceprevirRibavirinHumansAdverse effectErythropoietinHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgerychemistryErythropoietinHematinicsbusiness
researchProduct

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting …

2010

The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNβ-1a) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (RRMS). Patients aged 18—50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score ≤4.0) were assigned IFNβ therapy at the physician’s discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNβ-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for c…

Maleinterferon beta-1aKaplan-Meier EstimateRelapsing-RemittingNeuropsychological TestsCohort StudiesDisability EvaluationMedicineMale; Adolescent; Young Adult; Middle Aged; Kaplan-Meier Estimate; Cognition Disorders; Survival Analysis; Female; Disability Evaluation; Dose-Response Relationship Drug; Humans; Multiple Sclerosis Relapsing-Remitting; Prospective Studies; Cohort Studies; Disease Progression; Interferon-beta; Injections Subcutaneous; Neuropsychological Tests; Adult; Immunologic Factors; Endpoint DeterminationProspective StudiesProspective cohort studyinterferon beta multiple sclerosis cognitive impairmentSubcutaneousCognitive disorderHazard ratioMiddle AgedSettore MED/26 - NEUROLOGIANeurologyDisease ProgressionSettore MED/26 - NeurologiaFemaleDrugmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentEndpoint DeterminationInjections SubcutaneousLower riskInjectionsDose-Response RelationshipYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicineHumansImmunologic Factorscognitive functioncognitive impairmentExpanded Disability Status ScaleDose-Response Relationship Drugbusiness.industryInterferon beta-1aMcDonald criteriaOdds ratioInterferon-betamedicine.diseaseSurvival AnalysisSurgerydisabilityNeurology (clinical)businessCognition Disorderscognitive function; cognitive impairment; disability; disease progression; interferon beta-1a; multiple sclerosis
researchProduct

Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients w…

2011

Side effects of TNF neutralisation - mostly infectious complications - were recognized, the most important being pulmonary tuberculosis infections. gamma/ d T cells contribute to protective immune response against mycobacterium tuberculosis.The aim of the present study was to assess the expansion capacity of Vgamma9/Vdelta2 T cells from (tuberculin purified protein derivative (PPD) positive and PPD negative) patients with active rheumatoid arthritis (RA), and to examine the in vitro effect of infliximab on this lymphocyte subset.28 PPD negative RA patients were studied and compared with 14 PPD positive RA patients, 45 PPD-negative and 110 PPD-positive healthy volunteers. Cell separation, ex…

Malelcsh:Internal medicineTuberculosisT-Lymphocyteslcsh:MedicineArthritisTuberculinArthritis RheumatoidInterferon-gammaRheumatologyPsoriasismedicineHumanslcsh:RC31-1245Tuberculosis PulmonaryCells CulturedAgedAnkylosing spondylitisInterferon-gamma productionTumor Necrosis Factor-alphabusiness.industrylcsh:RAntibodies MonoclonalMiddle Agedmedicine.diseaseInfliximabInfliximabAntirheumatic AgentsRheumatoid arthritisImmunologyFemaleTumor necrosis factor alphabusinessmedicine.drug
researchProduct

Analysis of the immune response induced by a single xenoantigen in vivo

2004

Transgenic mice expressing human major histocompatibility complex (MHC) class II molecules would provide a valuable model system for studying murine anti-human MHC immune response. We have previously shown that skin from HLA-DR1 transgenic mice was rejected by control littermates and spleen cells from rejecting mice were able to proliferate to donor cells. The aim of this paper is to analyze the mechanism of recognition of this xenoantigen and the possible involvement of antibody response in anti-HLA-DR1 immune response. Control littermates were immunized with spleen cells from HLA-DR1 transgenic (TG) mice; at indicated times, xenoantigen-specific proliferation and IFNgamma production was a…

Malemedicine.drug_classTransgeneT-LymphocytesImmunologyEpitopes T-Lymphocytechemical and pharmacologic phenomenaSpleenMice TransgenicHuman leukocyte antigenMonoclonal antibodyMajor histocompatibility complexImmunoglobulin GInterferon-gammaMiceImmune systemAntigens HeterophilemedicineImmunology and AllergyAnimalsHumansCell ProliferationbiologyHLA-DR1 AntigenMolecular biologyPeptide Fragmentsmedicine.anatomical_structureImmunoglobulin MImmunoglobulin GImmunologyAntibody Formationbiology.proteinFemaleAntibodySpleen
researchProduct